SUMMARY Oral treatment with chenodeoxycholic acid causes dissolution of cholesterol gallstones in man. In order to determine the mechanism of this effect, we have measured 24-hour biliary lipid output, lipid composition of fasting gallbladder bile, and bile acid pool sizes before and during such treatment in six patients with radiolucent gallstones in functioning gallbladders. In all six patients, the degree of cholesterol saturation of fasting-state gallbladder bile was decreased during treatment to a level below the thermodynamic solubility line. This effect was due to a decrease in biliary cholesterol output, associated with conversion of more than 90% of the total bile acid pool to chenodeoxycholic acid. It could not be attributed to an increase in total bile acid pool size nor to an increase in biliary bile acid or phospholipid output.
the degree of cholesterol saturation of fasting-state gallbladder bile was decreased during treatment to a level below the thermodynamic solubility line. This effect was due to a decrease in biliary cholesterol output, associated with conversion of more than 90% of the total bile acid pool to chenodeoxycholic acid. It could not be attributed to an increase in total bile acid pool size nor to an increase in biliary bile acid or phospholipid output.
We have previously demonstrated that oral administration of chenodeoxycholic acid causes dissolution of cholesterol gallstones in man (Danzinger, Hofmann, Schoenfield, and Thistle, 1972; Thistle and Hofmann, 1973) . The initial observation (Danzinger et al, 1972) , made in a small uncontrolled series, has now been confirmed in a separate uncontrolled trial (Bell, Whitney, and Dowling, 1972) and in a larger controlled clinical trial . Cholic acid, the other primary bile acid synthesized by the human liver, did not cause gallstone dissolution in this controlled trial .
The exact mechanism for this therapeutic effect is not known, although it has been shown that chenodeoxycholic acid treatment makes fasting gallbladder bile less saturated in cholesterol (Thistle and Schoenfield, 1971; Danzinger, Hofmann, Thistle, and Schoenfield, 1973) , and that cholic acid does not have this effect (Thistle and Schoenfield, 1971) .
It is generally assumed that the mechanism of action involves an increase in biliary bile acid secretion rate, because total bile acid pool size is usually increased by bile acid feeding (Danzinger et al, 1973) ; but this would only decrease cholesterol saturation of bile if unaccompanied by an equivalent increase in biliary cholesterol secretion. Alternative explanations are a specific effect of chenodeoxycholic acid in enhancing biliary phospholipid secretion or a specific effect in decreasing biliary cholesterol secretion or both.
In order to differentiate among these possibilities, we measured the 24-hour biliary output of bile acids, phospholipid, and cholesterol in six patients with radiolucent gallstones in functioning gallbladders, using a duodenal perfusion technique, and repeated these measurements during oral treatment with chenodeoxycholic acid. Lipid composition of fasting gallbladder bile, bile acid pool sizes, and gallstone size were also measured before and during treatment.
Some of our findings were reported at the annual meeting of the British Society of Gastroenterology, 1973 (Northfield, Larusso, Thistle, and Hofmann, 1973 ).
Materials and Methods
All six patients had radiolucent gallstones in a functioning gallbladder, as demonstrated by a cholecystogram immediately before the first study. The group included three men and three postmenopausal women, ages 42 to 69 years (mean, 55 years); their weights ranged from 59-1 to 88-6 kg (mean 72-0 kg). Informed consent was obtained before the study.
Measurements of bile acid pool size, lipid composition of fasting gallbladder bile, and 24-hour biliary lipid output were made in all six patients before chenodeoxycholic acid treatment, and these measurements have already been reporced in detail (Northfield and Hofmann, 1975) . The patients restudied during treatment were subjects 1 to 6 inclusive in that report, and they have been assigned the same numbers in the present communication.
After completion of these baseline studies, the patients were discharged with instructions for an oral chenodeoxycholic acid regimen, the dose being adjusted to the maximum that did not cause diarrhoea. The dose taken ranged from 1 0 to 2-25 g/day (mean, 1-6 g/day). No instructions were given about diet. Dietary histories provided an estimate of cholesterol intake of 316 + 70 mg/day (mean ± SD) before the first study and 378 ± 139 mg/day before the second study. Another cholecystogram was taken after six months and gallstone size was Effect of chenodeoxycholic acid treatment in gallstone subjects compared without knowledge of treatment status.
The patients were readmitted to a metabolic unit for repeat studies after five to six months of treatment (patients 1, 2, 3, 5, and 6) or after two months (patient 4). Measurements of bile acid pool size and biliary lipid output were carried out in exactly the same order as in the pretreatment observations. The patients continued to take chenodeoxycholic acid during the studies according to the regimen that they had followed at home in the preceding months. Measurements of biliary lipid output were further modified to distinguish ingested chenodeoxycholic acid from secreted biliary bile acid. Ingested chenodeoxycholic acid, which was unconjugated, was extracted directly from duodenal samples and determined by gas-liquid chromatography as described previously (Northfield and Hofmann, 1975) , except that before the extraction procedure, a known amount of nordeoxycholic acid was added as an internal standard, and the saponification procedure was omitted. The value obtained for the concentration of free chenodeoxycholic acid was subtracted from the total bile acid concentration, which was determined enzymatically, in order to obtain the biliary output of conjugated bile acids. Apart from this, the methods used for all measurements and calculations were exactly the same as for the baseline studies (Northfield and Hofmann, 1975 Admirand and Small (1968) , if they lie above the continuous line. According to Dam and Hegardt (1971) and to Holzbach, March, Olszewski, and Holan (1973) , they are supersaturated with cholesterol if they lie above the broken line.
Results

LIPID COMPOSITION OF FASTING GALLBLADDER BILE
In all six patients, fasting gallbladder bile became less saturated with cholesterol ( fig 1; table I ). Before treatment, samples from patients 1 and 4 were supersaturated with cholesterol according to the criterion of Admirand and Small (1968) , and those from all six patients were supersaturated according to the criteria of Dam and Hegardt (1971) and of Holzbach, March, Olszewski, and Holan (1973) Admirand and Small (1968) 7-8 7-6 1-8 1-6 <0-05 Dam and Hegardt (1971) and Holzbach et al (1973) 16-0 ± 70 3-3 2-7 <0-005 (Salen, Nicolau, and Shefer, 1973) . according to criterion ofAdmirand and Small (1968),
In patients with gallstones, chenodeoxycholic acid before (---) and during (-) treatment. Cholesterol is considered to suppress hydroxy-methyl glutaryl saturation was calculated as described by Thomas and coenzyme A reductase, the rate-limiting enzyme for . Each line is a moving average of data cholesterol synthesis (Salen et al, 1973; Coyne, points, each point depicting secretion during a one-hour Bonorris, Goldstein, and Schoenfield, 1974) . Based collection period.
on isotope dilution studies, cholesterol synthesis is probably also suppressed' (Pedersen, Arnfred, and individually. There was a linear relationship between Hess Thaysen, 1974), but total body cholesterol the hourly rates of bile acid and cholesterol output pools do not appear to change (Hoffman, Hofmann, before and during treatment (fig 5) . The two and Thistle, 1974) , Chenodeoxycholic acid adminregression lines, before and during treatment, had istration has been shown to suppress cholic acid the same intercept, which was not significantly synthesis (Danzinger et al, 1973) , but as yet it is different from zero, but the slope was twice as steep not known whether chenodeoxycholic acid supbefore treatment as during treatment (p < 0-0005). presses its own synthesis in man. No information Thus, for an increase in bile acid output of 20 is available on the effect of chenodeoxycholic acid ,umol/kg per hour, there was an increase in cholesterol on the absorption of dietary or biliary cholesterol, output of 2 ,umol/kg per hour before treatment but so as yet our findings that chenodeoxycholic acid of only I ,umol/kg per hour during treatment.
diminishes cholesterol secretion in bile cannot be incorporated into an overall description ofcholesterol GALLSTONE SIZE metabolism in patients receiving chenodeoxycholic In patients 1 and 3, gallstone size was diminished acid. Bile acid output (jjmoles/kg-h)
Although gallstone dissolution by chenodeoxycholic acid appears to be entirely explicable by decreased cholesterol secretion in bile, it cannot be assumed that gallstone formation is caused solely by increased cholesterol secretion. We have previously shown, in a small series, that Caucasians with gallstones had the same total daily biliary cholesterol output as controls carefully matched for weight, age, and sex . Furthermore, control subjects had the same regression line for bile acid-cholesterol coupling as did untreated gallstone patients (Northfield and Hofmann, 1975) .
Since this decrease in biliary cholesterol output during chenodeoxycholic acid treatment was not accompanied by any consistent change in bile acid or phospholipid output, the degree of cholesterol saturation of bile was altered. We have previously shown, in both gallstone and control subjects, a curvilinear relationship between bile acid output and the degree of cholesterol saturation of bile, such that hepatic bile is supersaturated with cholesterol at low bile acid outputs and unsaturated at high bile acid outputs (Northfield and Hofmann, 1975) . During treatment with oral chenodeoxycholic acid, this curve was shifted downwards and to the left, so that samples were rarely supersaturated with cholesterol at low bile acid outputs and were more unsaturated at high bile acid outputs. For expression of these results (fig 4) , the line representing 100% saturation is based on the limit for cholesterol saturation defined in an in vitro system of bile acids, phospholipid, and cholesterol containing 80-95 % water by Admirand and Small (1968) . This figure is intended only to illustrate changes in the relative degree of cholesterol saturation at different bile acid outputs, and not the absolute position of the line for 100% saturation, since hepatic bile samples may contain more than 95 % water, and since more recent in vitro experiments (Dam and Hegardt, 1971; Mufson, Triyanond, Zarembo, and Ravin, 1972; Holzbach et al, 1973; Tamesue, Inoue, and Juniper, 1973) suggest that the true solubility line at thermodynamic equilibrium requires a slightly lower relative proportion of cholesterol than described by Admirand and Small (1968) . The effect of chenodeoxycholic acid in reducing the degree of cholesterol saturation of hepatic bile was reflected also in the results obtained from fasting gallbladder bile. In showing these results (fig 1) we have drawn both solubility lines. The absolute position of these in-vitro lines can be applied directly to fasting gallbladder bile, which almost invariably contains less than 95% water. Theoretically, for gallstone dissolution to occur, the lipid composition of bile entering the gallbladder would have to fall below the true solubility line at thermodynamic equilibrium. Our results are consistent with this prediction: before treatment, samples from all six patients lay above the line of Dam and Hegardt (1971) and of Holzbach et al (1973) , whereas during treatment samples from all six patients fell below this line.
Published clinical trials have used the maximal tolerated dose of chenodeoxycholic acid in order to have the best chance of a therapeutic effect. Because gallstone patients have a decreased bile acid pool size (Vlahcevic, Bell, Buhac, Farrar, and Swell, 1970) , it has been thought necessary to give a dose sufficient to increase bile acid pool size and secretion rate. In the present study, the dose of chenodeoxycholic acid was adjusted according to bowel function in exactly the same way as in the previous clinical trials (Danzinger et al, 1972; Thistle and Hofmann, 1973) reported from this institution, and treatment was continued during the repeat studies so as to reproduce the therapeutic situation as closely as possible. The results obtained confirm our previous study (Danzinger et al, 1973) in showing that an increase in bile acid pool size is not essential to make fasting gallbladder bile unsaturated in cholesterol or to dissolve gallstones. In addition, this study shows that bile acid secretion may actually decrease in patients whose gallstones are dissolving. What appears to be required is the conversion of a sufficient proportion of the total bile acid pool to chenodeoxycholic acid for a critical effect on biliary cholesterol output. The dose required for this has not been defined but may be considerably less than that currently used in clinical trials (about 20 mg/kg). This is important because of concern over a possible hepatotoxic effect of high doses of chenodeoxycholic acid. In the rhesus monkey, chenodeoxycholic acid at 20 mg/kg causes an increase in serum glutamicpyruvic transaminase levels, associated in some instances with histological changes of bile duct proliferation (Webster, Lancaster, Wease, Hofmann, and Baggenstoss, 1973) . In man, chenodeoxycholic acid at doses of 1 to 2 g/day causes a one-to two-fold increase in serum glutamic-oxaloacetic transaminase levels in about one-fourth of patients (Bellet al, 1972; Thistle and Hofmann, 1973) . However, the levels subsequently decrease to normal, and these increases are not associated with an alteration in any other liver function tests or with significant histological abnormality.
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